Medtronic, Inc. v. Guidant Corporation

465 F.3d 1360, 80 U.S.P.Q. 2d (BNA) 1558, 2006 U.S. App. LEXIS 25418, 2006 WL 2883360
CourtCourt of Appeals for the Federal Circuit
DecidedOctober 12, 2006
Docket2005-1515
StatusPublished
Cited by22 cases

This text of 465 F.3d 1360 (Medtronic, Inc. v. Guidant Corporation) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Medtronic, Inc. v. Guidant Corporation, 465 F.3d 1360, 80 U.S.P.Q. 2d (BNA) 1558, 2006 U.S. App. LEXIS 25418, 2006 WL 2883360 (Fed. Cir. 2006).

Opinions

SCHALL, Circuit Judge.

This is a patent case. Medtronic, Inc. (“Medtronic”) is a manufacturer of medical devices. It filed a declaratory judgment action in the United States District Court for the District of Delaware against Gui-dant Corporation, Guidant Sales Corporation, Eli Lilly & Company (“Eli Lilly”), and Mirowski Family Ventures L.L.C. In the action, Medtronic alleged that claims 15-26 of U.S. Reissue Patent No. 38,119 (“the RE'119 patent”), a reissue of U.S. Patent No. 4,928,688 (“the '688 patent”), are invalid by reason of violation of the rule against recapturing surrendered subject matter. The RE'119 patent claims a method and a pacemaker apparatus. Both relate to a “procedure for pacing of the heart in a particular way so as to improve its contraction pattern, and thereby augment the movement of blood through the heart.” RE'119 patent, col. 3, 11. 33-35. Mirowski Family Ventures L.L.C. and Eli Lilly are, respectively, the assignee and exclusive licensee of the patent. Guidant Corporation is a medical device manufacturer that was formed in 1994 when Eli Lilly divested certain assets, while Guidant Sales Corporation is a wholly owned subsidiary of Guidant Corporation. For ease of reference, we refer to the four defendants as “Guidant.”

Medtronic now appeals from the final judgment of the district court, following a [1365]*1365bench trial, that the RE'119 patent is not invalid. See Medtronic, Inc. v. Guidant Corp., 378 F.Supp.2d 503 (D.Del.2005). We affirm.

BACKGROUND

I.

A.

The heart is made up of four chambers: two atria and two ventricles. Electrical stimulations (depolarizations) within the chambers cause contractions within the heart that result in pumping. The electrical activity arises in the right atrium and is eventually transmitted to the ventricles. The period of time from depolarization of the atria to depolarization of the ventricles is called the “A-V delay period.”

Dr. Morton Mower is the inventor named on the RE'119 patent. His invention involves a method and apparatus for treating ventricular asynchrony, a condition in which a person has a defect in his or her heart ventricles. The defect causes the ventricles to contract at different times. This results in the loss of effectiveness in the pumping of blood. The method of the RE'119 patent works through a pacemaker device invented by Dr. Mower which either conditionally or unconditionally paces the two ventricles of the heart to cause simultaneous ventricular contractions. The “conditional embodiment” of the invention requires sensing a depolarization in a first ventricle, then waiting for a predetermined period of time to sense a depolarization in the second ventricle. If no depolarization is sensed in the second ventricle, the device stimulates, or “paces” the second ventricle with an electrical pulse. This embodiment of the invention is called “conditional” because the delivery of pacing pulses depends on the analysis of the cardiac signals. In the “unconditional embodiment,” depolarization is sensed in either ventricle and, as soon as depolarization in one ventricle is sensed, both ventricles are immediately paced. In the “unconditional embodiment,” one ventricle will be paced twice, once naturally and once by the device.

In the invention’s conditional embodiment, there are two apparatuses to sense electrical activity (“sensing electrodes”). There is one sensing electrode in each ventricle. In addition, there is at least one pacing electrode to pace the second ventricle. In the unconditional embodiment, there may be only one sensing electrode, as once a depolarization is sensed in one ventricle, the other ventricle is immediately paced. However, there are always two pacing electrodes, so that both ventricles may be paced at the same time.

B.

In the late 1980s, Dr. Mower asked Ron Cohn to prepare a patent application for his invention. On October 30, 1987, Cardiac Pacemakers, Inc. (now a wholly owned subsidiary of Guidant Corporation), where Dr. Mower was employed, forwarded Mr. Cohn’s draft application to attorney Thomas Nikolai to prepare a final application. On December 3, 1987, Mr. Nikolai asked Dr. Mower to review the draft application, explaining that he had added the concept of a “window of coincidence” — a delay between sensing and pacing.

On August 23, 1988, Mr. Cohn, pursuant to instructions from Dr. Mower, forwarded Dr. Mower’s comments to Mr. Nikolai, advising him that the essence of Dr. Mower’s invention was “a bi-ventricular pacer [that] continually senses the activity of both the left and right ventricles, and when activity is sensed in either ventricle the device immediately electrically paces the other or both ventricles.” With respect to Mr. Nikolai’s concern about a “window of coincidence,” Mr. Cohn stated that to have a delay between sensing and pacing would [1366]*1366undermine the purpose of the invention, which he said was to cause a simultaneous contraction of the ventricles. On August 31, 1988, Mr. Nikolai responded to Mr. Cohn’s letter with a letter to Dr. Mower, stating that he was “puzzled” about how the invention could sense the depolarization of one ventricle and then decide whether to pace the other ventricle without a delay period.

On September 9, 1988, Dr. Mower explained to Mr. Nikolai that while the mechanism would in some cases stimulate a ventricle that was in fact contracting normally, that was not a problem because “the artificial stimulus will fall harmlessly into the intrinsic depolarization.” Mr. Nikolai then amended the specification to include a description of the unconditional embodiment.

C.

On January 23, 1989, U.S. Patent Application No. 07/299,895 (“the '895 application”) was filed with the Patent and Trademark Office for Dr. Mower’s invention. As filed, the '895 application had twenty-two claims, including six independent claims (claims 1, 7, 15-17, and 19). Pertinent to this case, claims 1, 7, 15, and 16 of the '895 application stated:

1. A method for improving the hemo-dynamic efficiency of a sick heart comprising the steps of:
(a) detecting respective cardiac signals originating in the left and right ventricles of the heart;
(b) analyzing said cardiac signals and the absence thereof in an electronic control circuit;
(c) providing electrical pulses from a stimulating circuit controlled by said control circuit for effecting substantially simultaneous contraction of both ventricles.
7. An atrial-coupled bi-ventricular pacemaker for implantation or external use comprising atria and ventricular sensing means for detecting cardiac signals, a control circuit connected to said sensing means to analyze the cardiac signals and provide a control signal, a stimulating circuit for effecting simultaneous contraction of both ventricles in response to the control signal of the control circuit after a pre-determined A-V delay period.
15. A method for effecting simultaneous contraction of both left and right ventricles of a heart for improving hemodynamic efficiency comprising the steps of:
separately sensing cardiac signals from both left and right ventricles; and
stimulating at least one ventricle substantially simultaneously with the contraction of at least one other ventricle.
16.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In Re KOSTIC
Federal Circuit, 2025
In Re MCDONALD
Federal Circuit, 2022
Zimmer Surgical, Inc. v. Stryker Corp.
365 F. Supp. 3d 466 (D. Delaware, 2019)
Antares Pharma, Inc. v. Medac Pharma Inc.
771 F.3d 1354 (Federal Circuit, 2014)
AstraZeneca UK Ltd. v. Aurobindo Pharma Ltd.
703 F.3d 511 (Federal Circuit, 2012)
In Re Youman
679 F.3d 1335 (Federal Circuit, 2012)
Aia Engineering Ltd. v. Magotteaux Intern. S/A
657 F.3d 1264 (Federal Circuit, 2011)
AIA Engineering Ltd. v. Magotteaux International S/A
657 F.3d 1250 (Federal Circuit, 2011)
AIA Engineering Ltd. v. Magotteaux International SIA
745 F. Supp. 2d 852 (M.D. Tennessee, 2010)
Predicate Logic, Inc. v. Distributive Software, Inc.
544 F.3d 1298 (Federal Circuit, 2008)
Forest Laboratories, Inc. v. Ivax Pharmaceuticals, Inc.
501 F.3d 1263 (Federal Circuit, 2007)
MBO Laboratories, Inc. v. Becton, Dickinson & Co.
474 F.3d 1323 (Federal Circuit, 2007)
LUCENT TECHNOLOGIES INC. v. Gateway, Inc.
470 F. Supp. 2d 1163 (S.D. California, 2007)

Cite This Page — Counsel Stack

Bluebook (online)
465 F.3d 1360, 80 U.S.P.Q. 2d (BNA) 1558, 2006 U.S. App. LEXIS 25418, 2006 WL 2883360, Counsel Stack Legal Research, https://law.counselstack.com/opinion/medtronic-inc-v-guidant-corporation-cafc-2006.